semaglutide
Jump to navigation
Jump to search
See also: sémaglutide
English[edit]
Etymology[edit]
From [Term?] + -glutide (“glucagon-like peptide analog”).
(This etymology is missing or incomplete. Please add to it, or discuss it at the Etymology scriptorium.)
Noun[edit]
semaglutide (uncountable)
- (pharmacology) A peptide used in the treatment of diabetes and as an antiobesity medication.
- 2022 April 28, Gina Kolata, “Patients Taking Experimental Obesity Drug Lost More Than 50 Pounds, Maker Claims”, in The New York Times[1], →ISSN:
- Last year, the situation began to change when Novo Nordisk received approval from the Food and Drug Administration to market semaglutide. The drug can elicit a 15 percent to 17 percent weight loss in people with obesity.
- 2023 February 23, Jason Halford, “It may be the most effective anti-obesity drug yet – but even Wegovy is no ‘wonder cure’”, in The Guardian[2], →ISSN:
- But now a new generation of medications has arrived, based on a better understanding of the biological underpinnings of obesity. […] One of these medications – semaglutide, sold under the brand name Wegovy – will soon be available in UK chemists in the form of a weekly, self-administered injection.
- 2023 May 19, Sarah Zhang, “Ozempic’s Next Act”, in The Atlantic[3]:
- As semaglutide has skyrocketed in popularity, patients have been sharing curious effects that go beyond just appetite suppression. They have reported losing interest in a whole range of addictive and compulsive behaviors: drinking, smoking, shopping, biting nails, picking at skin.
Hyponyms[edit]
- Ozempic, Wegovy, Rybelsus (brand names)
Coordinate terms[edit]
diabetes drugs associated with weight loss in popular culture
high-profile pop-cultural weight-loss medications
Translations[edit]
Translations
|
French[edit]
Noun[edit]
semaglutide m (countable and uncountable, plural semaglutides)
- semaglutide: Alternative form of sémaglutide